Kaufman J H, Ezdinli E, Aungst C W, Stutzman L
Cancer. 1976 Mar;37(3):1283-92. doi: 10.1002/1097-0142(197603)37:3<1283::aid-cncr2820370308>3.0.co;2-o.
Sixty-three patients with Stage III and IV lymphocytic lymphoma were randomized for induction treatment between a single course of nitrogen mustard and a 14-day course of prednisone (conservative therapy) or sequential rotation of BCNU, nitrogen mustard and cytoxan with intermittent vincristine and prednisone for 6 months (extended therapy). Maintenance therapy by an oral alkylating agent (cytoxan or chlorambucil) with or without prednisone was given. Complete remission occurred in 75% of the conservative and 77% of the extended therapy group. The median duration of remission was similar, and greater than 27 months in both groups, and there was no difference in survival. At 1 year 80% of patients with no prior chemotherapy were in remission vs. 47% of patients with prior chemotherapy (p less than .01). No significant advantage for extended chemotherapy was found. The addition of vincristine was not helpful in induction and prednisone during maintenance did not improve the duration of remission or survival.
63例Ⅲ期和Ⅳ期淋巴细胞淋巴瘤患者被随机分为两组进行诱导治疗，一组接受单次氮芥治疗，另一组接受为期14天的泼尼松治疗（保守治疗），或接受卡莫司汀、氮芥和环磷酰胺序贯轮换治疗，并间断使用长春新碱和泼尼松治疗6个月（强化治疗）。给予口服烷化剂（环磷酰胺或苯丁酸氮芥）进行维持治疗，部分患者联合使用泼尼松。保守治疗组的完全缓解率为75%，强化治疗组为77%。两组的中位缓解持续时间相似，均超过27个月，生存率无差异。在未接受过化疗的患者中，1年时缓解率为80%，而接受过化疗的患者为47%（p<0.01）。未发现强化化疗有显著优势。添加长春新碱对诱导治疗无帮助，维持治疗期间使用泼尼松并未改善缓解持续时间或生存率。
